NFS 07
Alternative Names: NFS-07Latest Information Update: 18 Feb 2021
Price :
$50 *
At a glance
- Originator Neurophth Therapeutics
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Eye disorders
Most Recent Events
- 04 Feb 2021 NFS 07 is available for licensing as of 04 Feb 2021. https://www.neurophth.com/Business.html (Neurophth Therapeutics Pipeline, February 2021)
- 03 Feb 2021 Early research in Eye disorders in China (Intravitreous), prior to February 2021 (Neurophth Therapeutics Pipeline, February 2021)